NCIC CLINICAL TRIALS GROUP

MELANOMA

DISEASE SITE COMMITTEE MEETING AGENDA
(OPEN)
DELTA CHELSEA HOTEL, TORONTO, ON
ROOM: SCOTT
SUNDAY, APRIL 28, 2013 – 8:00 AM – 11:15 AM
CHAIR: TERESA PETRELLA, ALAN SPATZ

8:00 – 10:00 am
Welcome and Approval of Minutes
T. Petrella

CME goals/objectives
T. Petrella/ Alan Spatz

- Overview of immunotherapy for melanoma and mechanism of action and activity of PD1
  Omid Hamid
- Update of clinical trials and emerging results of anti-CTLA-4 agents
  Michael Smylie
- Management strategies for adverse events for immunotherapies
  Scott Ernst
- Round table future directions
  All

10:00 – 10:15 am
BREAK

10:15-10:30 am
TRIAL UPDATES:

NCIC CTG IND.202               Teresa Petrella
NCIC CTG MEC.3 / ECOG 1609     Teresa Petrella
NCIC CTG ME.11 / EORTC 18081   Teresa Petrella

10:30 – 11:15 am
NEW TRIAL PROPOSALS:

  Radiation + GSK targeted inhibitor for brain metastases  Teresa Petrella/ Arjun Sahgal
  Phase 2 trial of TH302                                   Anthony Joshua
  Surgical resection trial                                Francis Wright/ Marc Moncrieff

OTHER BUSINESS:
All

11:15 – 12:30 pm
Novartis Pipeline – Closed

12:30 – 1:00 pm
Melanoma Executive DSC Meeting – Closed

Meeting Adjourned